九洲藥業(603456.SH)全資子公司江蘇瑞科恢復生產
格隆匯6月8日丨九洲藥業(603456.SH)公佈,2019年4月18日,江蘇瑞科收到園區唯一供熱公司鹽城市凌雲海熱電有限公司的通知,因其自2019年4月18日起停止對外供熱,影響江蘇瑞科的車間生產,公司決定對江蘇瑞科生產線進行停產檢修升級。
2020年6月8日,江蘇瑞科收到鹽城市人民政府辦公室下發的《關於江蘇瑞科醫藥科技有限公司復產事項的批覆》:原則同意江蘇瑞科年產100噸亞胺培南、500噸柳氮磺吡啶、50噸索非布韋項目及相關的配套設施恢復生產。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.